Drug Profile
Research programme: colorectal cancer therapies - Abraxis BioScience/University of Southern California
Latest Information Update: 03 Dec 2019
Price :
$50
*
At a glance
- Originator University of Southern California
- Developer Celgene Corporation; University of Southern California
- Class
- Mechanism of Action
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported Colorectal cancer
Most Recent Events
- 20 Nov 2019 Celgene Corporation has been acquired by Bristol-Myers Squibb
- 16 Jul 2016 No recent reports of development identified for preclinical development in Colorectal-cancer in USA
- 16 Oct 2010 Abraxis BioScience has been acquired by Celgene Corporation